6th Apr 2022 7:00 am RNS Director Appointment6 Apr 2022 18:58
6th Apr 2022 7:00 am RNS Director Appointment
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the appointment to the Board of Felix Frueh, PhD ("Felix") as a Non-Executive Director.
Felix is a senior life sciences executive with in-depth expertise in corporate, regulatory, and commercialisation strategies, with a particular focus on precision medicine. He has over 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He has worked in the regulatory space for 18 years, including five years working with the FDA.
In addition to his FDA career, Felix oversaw the creation and operations of the world's largest next-generation, Clinical Laboratory Improvement Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-Founder and Partner of Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health.
Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans.
Matthew Walls, CEO of GENinCode Plc commented: "We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into the FDA as we start to look towards commericalisation in the US later this year, and his many years of experience in key roles in the industry will be a huge benefit to us. His depth of knowledge in precision medicine and regulatory affairs is second-to-none and we are looking forward to capitalising on his expertise."
Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented: "Our goal is to improve the current standard of care in cardiovascular disease worldwide through our unique portfolio of products, and Felix has the experience and expertise to help us achieve this. I am looking forward to working with him, as is the entire GENincode team, and welcome him to the Board."
Felix Frueh, PhD added: "I am thrilled to have been asked to join the Board of GENinCode at this critical stage. I have spent most of my career in the precision medicine space ...
https://www.lse.co.uk/rns/GENI/director-appointment-2zsg7qcopt7priq.html